The effects of glycemic index on prostate cancer progression in a xenograft mouse model

被引:0
作者
Galvan, Gloria Cecilia [1 ]
Macias, Everardo [2 ]
Sanders, Sergio [1 ]
Ramirez-Torres, Adela [1 ]
Stock, Shannon [3 ,4 ]
You, Sungyong [1 ,5 ]
Riera, Celine E. [6 ,7 ]
Tamukong, Patrick [1 ]
Smith-Warner, Stephanie A. [8 ,9 ]
Genkinger, Jeanine M. [10 ,11 ]
Luthringer, Daniel J. [12 ]
Freeman, Michael R. [1 ]
Freedland, Stephen J. [1 ,4 ]
机构
[1] Cedars Sinai Med Ctr, Dept Urol, Los Angeles, CA 90048 USA
[2] Duke Univ, Sch Med, Dept Pathol, Durham, NC USA
[3] Coll Holy Cross, Dept Math & Comp Sci, Worcester, MA USA
[4] Vet Affairs Hlth Care Syst, Dept Surg, Urol Sect, Durham, NC 27705 USA
[5] Cedars Sinai Med Ctr, Dept Computat Biomed, Los Angeles, CA USA
[6] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA USA
[7] Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA USA
[8] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA
[9] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[10] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA
[11] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[12] Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA USA
关键词
FACTOR-BINDING PROTEIN-3; GENE-EXPRESSION; CARBOHYDRATE; GROWTH; RISK; LOAD;
D O I
10.1038/s41391-023-00769-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Previously, we found low-carbohydrate diets slowed prostate cancer (PC) growth and increased survival vs. a Western diet in mice, by inhibiting the insulin/IGF-1 axis. Thus, we tested whether modifying carbohydrate quality to lower glycemic index (GI) without changing quantity results in similar benefits as with reduced quantity.Methods: Male SCID mice injected with LAPC-4 cells were single-housed and randomized when their tumors reached 200 mm(3) on average to a LoGI (48% carbohydrate kcal, from Hylon-VII) or HiGI Western diet (48% carbohydrate kcal, from sucrose). Body weight and tumor volume were measured weekly. Body composition was assessed 35 days after randomization. Blood glucose and serum insulin, IGF-1 and IGFBP3 were measured at study end when tumor volumes reached 800 mm(3). We analyzed gene expression of mice tumors by RNA-sequencing and human tumors using the Prostate Cancer Transcriptome Atlas.Results: There were no significant differences in tumor volume (P > 0.05), tumor proliferation (P = 0.29), and overall survival (P = 0.15) between groups. At 35 days after randomization, the LoGI group had 30% lower body fat (P = 0.007) despite similar body weight (P = 0.58). At sacrifice, LoGI mice had smaller livers (P < 0.001) and lower glucose (P = 0.15), insulin (P = 0.11), IGF-1 (P = 0.07) and IGF-1:IGFBP3 ratio (P = 0.05), and higher IGFBP3 (P = 0.09) vs. HiGI, although none of these metabolic differences reached statistical significance. We observed differential gene expression and pathway enrichment in mice tumors by diet. The most upregulated and downregulated gene in the LoGI group showed expression patterns more closely resembling expression in human benign prostate tissue vs. PC.Conclusions: In this single mouse xenograft model, consuming a low GI diet did not delay PC growth or survival vs. a high GI diet despite suggestions of decreased activation of the insulin/IGF-1 pathway. These data suggest that improving carbohydrate quality alone while consuming a high carbohydrate diet may not effectively slow PC growth.
引用
收藏
页码:348 / 354
页数:7
相关论文
共 50 条
  • [41] Therapeutic Effects of Hybrid Liposomes Against Xenograft Mouse Model of Colorectal Cancer In Vivo Due to Long-term Accumulation
    Ichihara, Hideaki
    Okumura, Masaki
    Matsumoto, Yoko
    ANTICANCER RESEARCH, 2016, 36 (11) : 5875 - 5882
  • [42] Assessment of a mouse xenograft model of primary colorectal cancer with special reference to perfluorooctane sulfonate
    Wimsatt, Jeffrey H.
    Montgomery, Caitlin
    Thomas, Laurel S.
    Savard, Charity
    Tallman, Rachel
    Innes, Kim
    Jrebi, Nezar
    PEERJ, 2018, 6
  • [43] Selective modulation of the prostaglandin F2α pathway markedly impacts on endometriosis progression in a xenograft mouse model
    Ahmad, Syed Furquan
    Akoum, Ali
    Horne, Andrew W.
    MOLECULAR HUMAN REPRODUCTION, 2015, 21 (12) : 905 - 916
  • [44] Progression of prostate cancer: Multiple pathways to androgen independence
    Devlin, Hong-Lin
    Mudryj, Maria
    CANCER LETTERS, 2009, 274 (02) : 177 - 186
  • [45] GPRC6A regulates prostate cancer progression
    Pi, Min
    Quarles, L. Darryl
    PROSTATE, 2012, 72 (04) : 399 - 409
  • [46] Effects of RNA Binding Proteins on the Prognosis and Malignant Progression in Prostate Cancer
    Hua, Xiaoliang
    Ge, Shengdong
    Chen, Juan
    Zhang, Li
    Tai, Sheng
    Liang, Chaozhao
    FRONTIERS IN GENETICS, 2020, 11
  • [47] Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer
    Lange, Tobias
    Oh-Hohenhorst, Su Jung
    Joosse, Simon A.
    Pantel, Klaus
    Hahn, Oliver
    Gosau, Tobias
    Dyshlovoy, Sergey A.
    Wellbrock, Jasmin
    Feldhaus, Susanne
    Maar, Hanna
    Gehrcke, Renate
    Kluth, Martina
    Simon, Ronald
    Schlomm, Thorsten
    Huland, Hartwig
    Schumacher, Udo
    SCIENTIFIC REPORTS, 2018, 8
  • [48] Cellular characterization of ultrasound-stimulated microbubble radiation enhancement in a prostate cancer xenograft model
    Al-Mahrouki, Azza A.
    Iradji, Sara
    Tran, William Tyler
    Czarnota, Gregory J.
    DISEASE MODELS & MECHANISMS, 2014, 7 (03) : 363 - 372
  • [49] Sabutoclax, a Mcl-1 Antagonist, Inhibits Tumorigenesis in Transgenic Mouse and Human Xenograft Models of Prostate Cancer
    Jackson, Roger S., II
    Placzek, William
    Fernandez, Ana
    Ziaee, Shabnam
    Chu, Chia-Yi
    Wei, Jun
    Stebbins, John
    Kitada, Shinichi
    Fritz, Gloria
    Reed, John C.
    Chung, Leland W.
    Pellecchia, Maurizio
    Bhowmick, Neil A.
    NEOPLASIA, 2012, 14 (07): : 656 - +
  • [50] Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression
    Tonry, Claire
    Armstrong, John
    Pennington, Stephen
    ONCOTARGET, 2017, 8 (09) : 15307 - 15337